1CZM
 
 | |
1AZM
 | |
1BZM
 | |
2KFT
 | |
1C8M
 | | REFINED CRYSTAL STRUCTURE OF HUMAN RHINOVIRUS 16 COMPLEXED WITH VP63843 (PLECONARIL), AN ANTI-PICORNAVIRAL DRUG CURRENTLY IN CLINICAL TRIALS | | Descriptor: | 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE, HUMAN RHINOVIRUS 16 COAT PROTEIN, ZINC ION | | Authors: | Chakravarty, S, Bator, C.M, Pevear, D.C, Diana, G.D, Rossmann, M.G. | | Deposit date: | 2000-05-26 | | Release date: | 2000-11-22 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | THE REFINED STRUCTURE OF A PICORNAVIRUS INHIBITOR CURRENTLY IN CLINICAL TRIALS, WHEN COMPLEXED WITH HUMAN RHINOVIRUS 16
to be published
|
|
1NA1
 | | The structure of HRV14 when complexed with Pleconaril | | Descriptor: | 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE, Coat protein VP1, Coat protein VP2, ... | | Authors: | Zhang, Y, Simpson, A.A, Bator, C.M, Chakravarty, S, Pevear, D.C, Skochko, G.A, Tull, T.M, Diana, G, Rossmann, M.G. | | Deposit date: | 2002-11-26 | | Release date: | 2003-12-16 | | Last modified: | 2024-05-22 | | Method: | X-RAY DIFFRACTION (3.3 Å) | | Cite: | Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds
J.Virol., 78, 2004
|
|
1NCQ
 | | The structure of HRV14 when complexed with pleconaril, an antiviral compound | | Descriptor: | 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE, COAT PROTEIN VP1, COAT PROTEIN VP2, ... | | Authors: | Zhang, Y, Simpson, A.A, Bator, C.M, Chakravarty, S, Pevear, D.C, Skochko, G.A, Tull, T.M, Diana, G, Rossmann, M.G. | | Deposit date: | 2002-12-05 | | Release date: | 2003-12-16 | | Last modified: | 2024-05-22 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds
J.Virol., 78, 2004
|
|
1ND2
 | | The structure of Rhinovirus 16 | | Descriptor: | MYRISTIC ACID, ZINC ION, coat protein VP1, ... | | Authors: | Zhang, Y, Simpson, A.A, Bator, C.M, Chakravarty, S, Pevear, D.C, Skochko, G.A, Tull, T.M, Diana, G, Rossmann, M.G. | | Deposit date: | 2002-12-06 | | Release date: | 2003-12-16 | | Last modified: | 2024-02-14 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds
J.Virol., 78, 2004
|
|
1NCR
 | | The structure of Rhinovirus 16 when complexed with pleconaril, an antiviral compound | | Descriptor: | 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE, MYRISTIC ACID, ZINC ION, ... | | Authors: | Zhang, Y, Simpson, A.A, Bator, C.M, Chakravarty, S, Pevear, D.C, Skochko, G.A, Tull, T.M, Diana, G, Rossmann, M.G. | | Deposit date: | 2002-12-05 | | Release date: | 2003-12-16 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds
J.Virol., 78, 2004
|
|
1ND3
 | | The structure of HRV16, when complexed with pleconaril, an antiviral compound | | Descriptor: | 3-{3,5-DIMETHYL-4-[3-(3-METHYL-ISOXAZOL-5-YL)-PROPOXY]-PHENYL}-5-TRIFLUOROMETHYL-[1,2,4]OXADIAZOLE, ZINC ION, coat protein VP1, ... | | Authors: | Zhang, Y, Simpson, A.A, Bator, C.M, Chakravarty, S, Pevear, D.C, Skochko, G.A, Tull, T.M, Diana, G, Rossmann, M.G. | | Deposit date: | 2002-12-06 | | Release date: | 2003-12-16 | | Last modified: | 2024-02-14 | | Method: | X-RAY DIFFRACTION (2.8 Å) | | Cite: | Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds
J.Virol., 78, 2004
|
|
6B5N
 | | Structure of PfCSP peptide 25 with human protective antibody CIS43 | | Descriptor: | CIS43 Fab Heavy chain, CIS43 Fab Light chain, pfCSP peptide 25: ASN-VAL-ASP-PRO-ASN-ALA-ASN-PRO-ASN-VAL-ASP | | Authors: | Pancera, M, Weidle, C. | | Deposit date: | 2017-09-29 | | Release date: | 2018-03-21 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (1.98 Å) | | Cite: | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat. Med., 24, 2018
|
|
6B5O
 | | Structure of PfCSP peptide 29 with human protective antibody CIS43 | | Descriptor: | CIS43 Fab Heavy chain, CIS43 Fab Light chain, PfCSP peptide 29: ASN-PRO-ASN-ALA-ASN-PRO-ASN-ALA-ASN | | Authors: | Pancera, M, Weidle, C. | | Deposit date: | 2017-09-29 | | Release date: | 2018-03-21 | | Last modified: | 2018-04-25 | | Method: | X-RAY DIFFRACTION (2.194 Å) | | Cite: | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat. Med., 24, 2018
|
|
6B5L
 | | Structure of PfCSP peptide 20 with human protective antibody CIS43 | | Descriptor: | CIS43 Fab Heavy chain, CIS43 Fab Light Chain, PfCSP peptide 20: ASN-PRO-ASP-PRO-ASN-ALA-ASN-PRO-ASN-VAL | | Authors: | Pancera, M, Weidle, C. | | Deposit date: | 2017-09-29 | | Release date: | 2018-03-21 | | Last modified: | 2018-04-25 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat. Med., 24, 2018
|
|
6B5S
 | | Structure of PfCSP peptide 25 with human antibody CIS42 | | Descriptor: | AMMONIUM ION, CIS42 Fab Heavy chain, CIS42 Fab Light chain, ... | | Authors: | Pancera, M, Weidle, C. | | Deposit date: | 2017-09-29 | | Release date: | 2018-03-21 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (1.983 Å) | | Cite: | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat. Med., 24, 2018
|
|
6B5P
 | | Structure of PfCSP peptide 20 with human antibody CIS42 | | Descriptor: | CIS42 Fab Heavy chain, CIS42 Fab Light chain, pfCSP peptide 20: ASN-PRO-ASP-PRO-ASN-ALA-ASN-PRO-ASN-VAL-ASP | | Authors: | Pancera, M, Weidle, C. | | Deposit date: | 2017-09-29 | | Release date: | 2018-03-21 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.297 Å) | | Cite: | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat. Med., 24, 2018
|
|
6B5R
 | | Structure of PfCSP peptide 21 with human antibody CIS42 | | Descriptor: | CIS42 Fab Heavy chain, CIS42 Fab Light chain, PfCSP peptide 21: ASN-PRO-ASP-PRO-ASN-ALA-ASN-PRO-ASN-VAL-ASP-PRO-ASN | | Authors: | Pancera, M, Weidle, C. | | Deposit date: | 2017-09-29 | | Release date: | 2018-03-21 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (1.775 Å) | | Cite: | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat. Med., 24, 2018
|
|
6B5M
 | |
6B5T
 | | Structure of PfCSP peptide 29 with human antibody CIS42 | | Descriptor: | AMMONIUM ION, CIS42 Fab Heavy chain, CIS42 Fab Light chain, ... | | Authors: | Pancera, M, Weidle, C. | | Deposit date: | 2017-09-29 | | Release date: | 2018-03-21 | | Last modified: | 2018-04-25 | | Method: | X-RAY DIFFRACTION (2.222 Å) | | Cite: | A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.
Nat. Med., 24, 2018
|
|
